CRB-913 brain levels are 15-fold lower than monlunabant in lean miceDose-response demonstrated for a range of 5 to 80 ...

"Our preclinical data highlight the potential of azelaprag as a novel oral therapy for obesity," said Kristen Fortney, Ph.D., CEO and co-founder of BioAge. “Our two presentations provide evidence ...

Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term ...

Q3 2024 Earnings Call Transcript November 7, 2024 Skye Bioscience, Inc. beats earnings expectations. Reported EPS is $-0.1, expectations were $-0.25. Operator: Ladies and gentlemen, thank you for ...

BioAge’s lead product candidate, azelaprag, is an orally available small molecule agonist of APJ that was ... in patients on obesity therapy with incretin drugs. BioAge is also developing ...

These hormones have several functions. For example, they: In people with type 2 diabetes, incretin levels are absent or lower than they should be. Peptide medications, like GLP-1 and GLP-1/GIP ...

The data are being presented as a Poster Presentation titled:“Induction and Maintenance Regimens with CB1 Inverse Agonist CRB-913 ... a maintenance therapy post incretin analog induction treatment.

Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials. Read why CRBP stock is ...